P53 PROTEIN ACCUMULATES IN CUSHINGS ADENOMAS AND INVASIVE NONFUNCTIONAL ADENOMAS

被引:62
作者
BUCKLEY, N
BATES, AS
BROOME, JC
STRANGE, RC
PERRETT, CW
BURKE, CW
CLAYTON, RN
机构
[1] KEELE UNIV, N STAFFORDSHIRE HOSP CTR, POSTGRAD MED SCH, STOKE ON TRENT ST4 7QB, ENGLAND
[2] RADCLIFFE INFIRM, DEPT ENDOCRINOL, OXFORD OX2 6HE, ENGLAND
关键词
D O I
10.1210/jc.79.5.1513
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The p53 protein, a negative regulator of cell growth, plays an important role in the pathogenesis of many human tumours following gene mutation and/or deletion. We screened a large number of sporadic pituitary tumours for p53 protein accumulation suggestive of gene mutation. Samples were divided into benign adenomas (n=95) and invasive tumours with local or distant invasion (n=26). All main tumour classes were represented. Putative p53 mutations were detected by immunohistochemistry on paraffin-embedded sections using polyclonal CM-1 and monoclonal DO-7 and PAb1801 antibodies. Results were compared to normal post-mortem pituitary tissue controls (n=17). p53 protein accumulation was detected in invasive tumours (16%), but only in corticotrophinomas (2/4) and non-functional tumours (4/15). In non-invasive adenomas, protein accumulation was observed only in ACTH-secreting tumours where 50% were positive (16/32). No protein accumulation was identified in any control tissue. These results indicate that p53 protein accumulation may play a role in the development of Cushings adenomas and in the progression of non-functional tumours to the invasive state.
引用
收藏
页码:1513 / 1516
页数:4
相关论文
共 27 条
  • [1] CLINICALLY NONFUNCTIONING PITUITARY-TUMORS ARE MONOCLONAL IN ORIGIN
    ALEXANDER, JM
    BILLER, BMK
    BIKKAL, H
    ZERVAS, NT
    ARNOLD, A
    KLIBANSKI, A
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1990, 86 (01) : 336 - 340
  • [2] ALI IU, 1994, CANCER RES, V54, P1
  • [3] ISOLATION OF HUMAN-P53-SPECIFIC MONOCLONAL-ANTIBODIES AND THEIR USE IN THE STUDIES OF HUMAN P53 EXPRESSION
    BANKS, L
    MATLASHEWSKI, G
    CRAWFORD, L
    [J]. EUROPEAN JOURNAL OF BIOCHEMISTRY, 1986, 159 (03): : 529 - 534
  • [4] BENNETT WP, 1993, CANCER RES, V53, P4817
  • [5] HUMAN P53 IS PHOSPHORYLATED BY P60-CDC2 AND CYCLIN-B-CDC2
    BISCHOFF, JR
    FRIEDMAN, PN
    MARSHAK, DR
    PRIVES, C
    BEACH, D
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (12) : 4766 - 4770
  • [6] MOLECULAR-GENETIC STUDIES OF SPORADIC PITUITARY-TUMORS
    BOGGILD, MD
    JENKINSON, S
    PISTORELLO, M
    BOSCARO, M
    SCANARINI, M
    MCTERNAN, P
    PERRETT, CW
    THAKKER, RV
    CLAYTON, RN
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1994, 78 (02) : 387 - 392
  • [7] CUNNINGHAM J, 1992, CANCER RES, V52, P1974
  • [8] ESRIG D, 1993, AM J PATHOL, V143, P1389
  • [9] ACTIVATING MUTATIONS FOR TRANSFORMATION BY P53 PRODUCE A GENE-PRODUCT THAT FORMS AN HSC70-P53 COMPLEX WITH AN ALTERED HALF-LIFE
    FINLAY, CA
    HINDS, PW
    TAN, TH
    ELIYAHU, D
    OREN, M
    LEVINE, AJ
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 1988, 8 (02) : 531 - 539
  • [10] Hardy J., 1979, RECENT ADV DIAGNOSIS, P375